

FIG. 1





FIG. 2







FIG. 3A

FIG. 3B

Subtraction of self-self background binding signal				mAb-1 Binding to the Pre-complex of mAb-2 & hPDGF-BB (R&D)																	
anti-PDGF-BB (AbID)	mAb Capture d1 (nm)	human Fc Blocking mAb (nm)	mAb#	15	1	14	5	2	3	4	6	7	9	11	12	13	16	17	10	8	18
H4H13167P	1.6	0.01	15	0.0	0.0	0.0	1.2	1.0	0.8	1.1	0.9	0.8	1.1	0.8	0.9	0.9	1.0	0.8	1.0	0.6	0.5
H4H13127P	1.5	0.00	1	0.1	0.0	0.1	1.2	1.2	0.9	1.6	1.1	1.1	1.4	1.0	1.5	1.1	1.2	1.1	1.2	0.8	0.6
H4H13166P	1.3	0.00	14	0.0	0.0	0.0	0.1	0.9	0.7	1.1	0.9	0.8	1.0	0.8	1.0	0.6	0.8	0.7	0.8	0.5	0.4
H4H13148P	1.6	-0.01	5	1.5	0.7	0.2	0.0	0.1	0.1	0.0	0.1	0.3	0.2	0.1	0.1	0.1	0.1	0.2	0.5	0.7	0.6
H4H13132P	1.3	0.00	2	1.0	0.9	0.8	0.0	0.0	-0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	-0.1	-0.1	0.3	0.3
H4H13143P	1.3	0.00	3	1.2	1.2	0.9	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.4	0.4
H4H13145P	1.5	-0.01	4	0.9	0.7	0.6	-0.1	0.0	-0.1	0.0	-0.1	-0.1	-0.1	-0.1	0.0	0.0	0.0	-0.1	-0.1	0.4	0.3
H4H13151P	1.4	0.00	6	1.3	1.2	1.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.4	0.4
H4H13152P	1.5	-0.01	7	0.8	0.7	0.7	0.0	0.0	-0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.1	-0.1	0.4	0.4
H4H13155P	1.7	-0.02	9	1.2	1.0	0.7	-0.1	0.0	-0.1	0.1	0.0	0.0	0.0	-0.1	0.0	0.0	0.1	0.0	0.0	0.4	0.4
H4H13159P	1.6	0.00	11	1.3	1.2	0.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.4	0.4
H4H13162P	1.3	0.02	12	1.2	1.1	0.9	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.3
H4H13163P	1.3	0.00	13	1.1	1.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.1	0.0	0.4	0.4
H4H13169P	1.3	0.01	16	1.1	1.1	0.8	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.3
H4H13170P	1.2	0.02	17	1.0	1.1	0.7	-0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.3
H4H13157P	1.3	0.00	10	1.2	1.1	0.9	0.2	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.3	0.2
H4H13153P	1.2	0.00	8	0.1	0.1	0.0	0.0	0.0	-0.1	0.0	-0.1	-0.2	0.0	-0.1	0.0	0.0	0.0	-0.2	-0.1	0.0	0.1
(-)isotype control	1.3	0.01	18	0.1	0.0	0.0	-0.1	0.0	-0.2	0.0	-0.1	-0.3	-0.2	-0.1	0.0	-0.1	0.0	-0.2	-0.1	0.0	0.0



H4H (-) control
bi-directional competition
self-self competition control

FIG. 4A





FIG. 4B





7/41


FIG. 4C

AB PID	Ab blocking of 60pM Biot-PDGF-BB (dimer) on 1 ug/ml hPDGFRb-mmH, IC50 (M)	100nM Ab blocking of 60pM Biot-PDGF-BB (dimer) on 1 ug/ml hPDGFRb-mmH, % blocking	Ab blocking of 100pM Biot-PDGF-AB (dimer) on 1 ug/ml hPDGFRb-mmH, IC50 (M)	100nM Ab blocking of 100pM Biot-PDGF-AB (dimer) on 1 ug/ml hPDGFRb-mmH, % blocking
H4H13148P	2.3E-10	102	INC	73
H4H13145P	3.0E-10	101	4.6E-09	97
H4H13132P	1.8E-09	96	1.4E-08	92
H4H13162P	5.5E-10	75	NB	1
H4H13151P	6.4E-10	90	NB	-2
H4H13157P	2.8E-09	50	1.1E-07	57
H4H13163P	1.3E-08	48	1.9E-07	68
H4H13167P	6.4E-10	66	NB	2
H4H13169P	1.7E-09	67	NB	14
H4H13155P	2.6E-09	61	NB	2
H4H13166P	2.8E-09	50	NB	2
H4H13127P	5.1E-10	40	1.5E-08	29
H4H13159P	2.0E-08	29	NB	2
H4H13143P	NB	18	NB	13
H4H13152P	NB	3	NB	-7
H4H13170P	NB	1	NB	1
H4H13153P	NB	-17	NB	-9
CONTROLS				
a-PDGF-BB+AB goat poly (abcam, ab34074)	7.7E-09	103	7.4E-09	99
a-PDGF-BB+AB goat poly (R&D, AF-220-NA)	7.6E-11	102	1.1E-10	100
a-PDGF-BB+AB (R&D, MAB1739)	8.7E-10	87	8.0E-09	93
isotype - hlgG4 (REGN 1945)	NB	-6	NB	21
isotype - mlgG4 (REGN 751)	NB	-5	NB	18
Theoretical bottom	<3.0E-11		<5.0E-11	
Blocks >70%		>70%		>70%
Blocks between 45-70%		40-75%		40-75%
Block <25% - IC50 is not shown, considered to be Non-Blocker (NB)				

8/41











FIG. 6A






FIG. 6C





FIG. 7



	EC50(pM)
SinoBio Mf-BB	167
KingFisher Mf-BB	64
R&D hu-BB	41

500pM BB Constant	H4H13132P		H4H13145P	
	IC50(pM)	% Inhibition	IC50(pM)	% Inhibition
SinoBio Mf-BB	781	100	16	100
KingFisher Mf-BB	8864	98.5	316	99.1
R&D hu-BB	57590	78.8	70490	91.3

FIG. 8

			Human PDGF-BB homodimer (R&D)					Monkey PDGF-BB homodimer (Kingfisher)					Monkey PDGF-BB Fc homodimer-mouse Fc (IgG1) tag (Sino Biological)							
Ab ID # / REGN #	Lot #	Capture Surface Description	mAb Capture (RU)	30nM hPDG F-BB (R&D) Bound (RU)	ka (1/MS)	kd (1/s)	KD (M)	t½ (min)	mAb Capture (RU)	30nM mPDG F-BB (Kingfisher) Bound (RU)	ka (1/MS)	kd (1/s)	KD (M)	t½ (min)	mAb Capture (RU)	30nM mPDG F-BB (Sino) Bound (RU)	ka (1/MS)	kd (1/s)	KD (M)	t½ (min)
H4H13 132P	L1	Anti PDGF-B	249 ± 1.7	260E+06	5.01E-05	1.93E-11	230.5	257.6 ± 1.5	50.3	4.31E+06	4.17E-05	9.67E-12	277.2	271.2 ± 2.6	116.7	4.09E+05	1.05E-05	2.56E-11	1102.3	
H4H13 145P	L2	Anti PDGF-B	297.8 ± 21.5	1.09E+06	3.09E-05	2.82E-11	374.2	300.1 ± 13.5	73.4	9.30E+05	1.50E-05	1.61E-11	769.7	340 ± 11.4	151.5	4.04E+05	1.08E-05	2.68E-11	1066.7	
REGN1 945	L49	Anti FeD1	356.7 ± 0.8	NB	NB	NB	NB	359.9 ± 1.1	6.8	NB	NB	NB	NB	367.4 ± 0.5	-1.4	NB	NB	NB	NB	

17/41




FIG. 10




FIG. 11






FIG. 12




SUBSTITUTE SHEET (RULE 26)

20/41



22/41

FIG. 13B



SUBSTITUTE SHEET (RULE 26)

FIG. 14




FIG. 15





FIG. 16


25/41




Day 30 PK Parameters								
C57BL/6 WT Mice								
Dose (mg/kg)	Drug	T _{1/2} (day)	C _{max} (µg/mL)	C _{max, D} (kg*µg/ml/mg)	AUC _{last} (d*µg/mL)	AUC _{last/D} (d*µg/ml)/(mg/kg)	CL _{F, obs} (mL/day/kg)	n
10	REGN13335	8.14 ± 0.62	104 ± 2.4	10.4 ± 0.24	1300 ± 49	130 ± 4.9	7.14 ± 0.37	3
	H4H13132P	11.7 ± 0.71	129 ± 4.8	12.9 ± 0.48	1840 ± 50	184 ± 5	4.48 ± 0.13	4
	Isotype Ctrl.	10.4 ± 1.3	124 ± 1.8	12.4 ± 0.18	1420 ± 91	142 ± 9.1	6.03 ± 0.63	2
1	REGN13335	5.33 ± 0.15	10.5 ± 0.27	10.5 ± 0.27	94 ± 1.5	94 ± 1.5	10.5 ± 0.18	4
	H4H13132P	12 ± 0.1	12.2 ± 0.29	12.2 ± 0.29	136 ± 5.7	136 ± 5.7	6 ± 0.26	3
	Isotype Ctrl.	12.6 ± 0.53	9.6 ± 0.32	9.6 ± 0.32	140 ± 2.9	140 ± 2.9	5.85 ± 0.21	3
0.1	REGN13335	3.17 ± 0.12	0.563 ±	5.61 ± 0.2	2.69 ± 0.16	26.9 ± 1.6	35.3 ± 2	4
	H4H13132P	11.8 ± 0.6	0.613 ±	6.13 ± 0.21	7.8 ± 0.19	78 ± 1.9	10.6 ± 0.4	4
	Isotype Ctrl.	8.43 ± 0.96	0.515 ±	5.18 ± 0.24	6.45 ± 0.94	64.5 ± 9.4	14.7 ± 2.5	2

SUBSTITUTE SHEET (RULE 26)


FIG. 17





28/41

FIG. 19



29/41




FIG. 20






FIG. 21







FIG. 22

FIG. 23










FIG. 25












FIG. 30




FIG. 31




FIG. 32

